TenX Keane Acquisition Merger with Citius Pharmaceuticals Oncology Subsidiary to Form Citius Oncology, Inc.

Chimerix Acquires Oncoceutics

January 7, 2021

Biotechnology

Chimerix (NASDAQ: CMRX) acquired clinical-stage Oncoceutics, gaining the late-stage oncology candidate ONC201 to expand its oncology pipeline. The deal closed January 7, 2021, for $78 million (half stock, half cash) plus potential milestones and royalties.

Sorrento Therapeutics Acquires ACEA Therapeutics

June 1, 2021

Biotechnology

Sorrento Therapeutics completed the acquisition of ACEA Therapeutics, making ACEA a wholly owned subsidiary and issuing Sorrento common stock plus contingent milestone and royalty payments. The deal adds multiple clinical- and preclinical-stage new chemical entities (including abivertinib) to Sorrento's oncology and immunotherapy pipeline and expands its development and manufacturing footprint in China and North America.

Symeres Acquires Oncolines

January 10, 2023

Healthcare Services

Symeres, the Netherlands-headquartered transatlantic CRO & CDMO backed by Keensight Capital, has acquired Oncolines, an Oss-based oncology-focused CRO that provides early biology services and cell-line profiling assays. The add-on expands Symeres' oncology and precision-medicine biology capabilities and brings Oncolines' ~20 employees into the Symeres platform (part of NTRC Holding), increasing the group's integrated drug-discovery offering and proforma revenues to over €100m.

BioNTech Acquires Neon Therapeutics

January 16, 2020

Biotechnology

BioNTech SE will acquire Neon Therapeutics, Inc. in an all-stock transaction valued at approximately $67.0 million. Neon, a Cambridge-based developer of neoantigen-targeted T cell therapies, will become a wholly owned subsidiary of BioNTech to expand BioNTech’s T cell therapy capabilities and U.S. presence.

Merck Acquires Terns Pharmaceuticals in $6.7 Billion Deal

March 26, 2026

Biotechnology

Merck has agreed to acquire Terns Pharmaceuticals for approximately $6.7 billion to accelerate its expansion in blood cancer treatments, particularly chronic myeloid leukemia. The deal centers on Terns’ lead asset, TERN-701, an investigational oral allosteric BCR::ABL1 inhibitor currently in Phase 1/2, with the transaction expected to close in the second quarter of 2026 subject to approvals.

Axonius Acquires Cynerio

July 30, 2025

Cybersecurity

Axonius has acquired Cynerio, a specialist in medical-device and healthcare IoT security, to accelerate the company's expansion into the healthcare market. Deal terms were reported at about $180 million (potentially rising to $250 million on milestones), while Axonius' announcement described the transaction as "more than $100 million" in a cash-and-stock deal.